Informed Consent for Participation in an Interventional Clinical Trial

Procedure Name

Form Sections

Section 1info grid

Research Institution / Sponsor

Principal Investigator

Participant Full Legal Name

Date of Birth

Full Study Title

ClinicalTrials.gov Identifier (NCT Number)

IRB Protocol Number

Reviewing IRB / Ethics Committee

Clinical Trial Phase

IRB Approval Date

Section 2text block

Section 3text block

Section 4text block

Section 5list block

Section 6list block

Section 7text block

Section 8text block

Section 9text block

Section 10text block

Section 11text block

Section 12text block

Section 13text block

Section 14text block

Section 15signature block

Participant / LAR Signature

Relationship (if LAR)

Principal Investigator / Delegated Researcher Signature

Witness Signature (if required by IRB)

Date and Time of Consent

Consent Form Version Date Used

Informed Consent for Participation in an Interventional Clinical Trial

Study and Participant Information

Research Institution / Sponsor

Principal Investigator

Participant Full Legal Name

Date of Birth

Full Study Title

ClinicalTrials.gov Identifier (NCT Number)

IRB Protocol Number

Reviewing IRB / Ethics Committee

Clinical Trial Phase

IRB Approval Date

Voluntary Nature of Participation

Your participation in this research study is completely voluntary. You may choose not to participate, and if you agree to participate, you may withdraw your consent and stop participating at any time without penalty or loss of any benefits to which you are otherwise entitled. Your decision to participate or not will not affect your current or future medical care at this institution. Withdrawing from the study will not affect your legal rights. In the event of withdrawal, the study team may need to retain and analyze data already collected from you if required by the regulatory protocol or the IRB.

Purpose and Background of the Research

You are being invited to participate in a research study to evaluate [the safety and efficacy of an investigational drug/device/intervention as specified in the study protocol]. Research studies are conducted to generate evidence about whether new treatments, devices, or approaches are safe, effective, and better than existing options. Clinical trials progress through phases: Phase I studies primarily assess safety and dosing in small groups; Phase II studies evaluate preliminary efficacy and safety in larger groups; Phase III studies compare the new treatment to existing standard-of-care treatment in large, randomized, controlled populations; Phase IV studies monitor long-term safety after regulatory approval. You are invited to participate in a Phase [X] study, meaning [the study team should describe the specific context of this phase].

Randomization and Blinding

This study is a randomized controlled trial. If you agree to participate, you will be randomly assigned (like a coin toss) by a computer to one of the study arms: (1) the experimental treatment group, which receives the investigational drug/device; or (2) the control group, which receives [the current standard treatment / an active comparator / a placebo (inactive substance)]. You will have an approximately equal chance of being assigned to either group. This study [is / is not] double-blinded: [In a double-blind study, neither you nor the study team members know which treatment you are receiving until the study code is broken at the pre-specified analysis time. / You and/or the study team will know which treatment you are receiving.] Randomization and blinding are essential to ensure that the study results reflect the true effect of the treatment and are not influenced by expectation or bias.

Study Procedures and Time Commitment

Screening visit: medical history review, physical examination, laboratory tests, ECG, and imaging as specified in the protocol, to confirm eligibility criteria.

Investigational treatment administration: study drug or device delivered on the schedule specified in the protocol (e.g. daily oral tablet, weekly IV infusion, single-device implant).

Follow-up visits: scheduled clinic visits at defined intervals for safety assessments, blood and urine tests, questionnaires, and imaging scans as per the protocol visit schedule.

Patient diary: daily electronic or paper diary recording symptoms, medication use, and adverse events as instructed by the study team.

Total time commitment: estimated [X] hours over [Y] weeks/months of active participation plus [Z] months of long-term safety follow-up.

Foreseeable Risks and Discomforts

Risks of the investigational drug or device: [The study team must insert the specific known and potential risks based on preclinical data and Phase I/II experience as listed in the Investigator's Brochure and protocol, e.g.: nausea, fatigue, elevated liver enzymes, specific organ toxicities, known adverse drug reactions].

Risks of the study procedures: phlebotomy-related bruising, discomfort, or haematoma from frequent blood draws; low-dose radiation exposure from protocol-required CT scans; risks specific to any invasive procedure (biopsy, lumbar puncture) required by the protocol.

Potential unknown risks: because the investigational agent is new, there may be unforeseen risks not identified in preclinical or earlier-phase studies. New safety information identified during the study will be disclosed to all participants promptly.

Placebo risk: participants assigned to the control or placebo arm will not receive the investigational treatment during the blinded phase. If the investigational treatment proves effective, delayed access to it may be a disadvantage.

Reproductive risk: the investigational drug may be harmful to a developing fetus or infant. Women of childbearing potential must use two forms of highly effective contraception for the duration of the study and for [X] months following the last dose. Breastfeeding is not permitted during study participation.

Potential Benefits

There may be no direct medical benefit to you from participating in this study. The investigational treatment may or may not improve your condition; this is precisely what the study is designed to determine. The knowledge gained from this study may benefit future patients with this condition. The information collected about your health through study visits and tests may be of indirect benefit by enabling closer monitoring of your condition during the study period.

Confidentiality and Data Privacy (HIPAA Authorization)

Your participation in this study and your personal health information will be kept confidential to the extent permitted by law. Study records will be identified only by a participant code number. Your identifying information will be kept in a separate, locked file accessible only to the study team. The study sponsor, the IRB, and regulatory authorities (FDA, EMA) may inspect study records. A Certificate of Confidentiality from the [relevant federal agency] protects identifiable research information from compelled disclosure in civil, criminal, or administrative proceedings. Research data will be retained for a minimum of 15 years following study completion as required by federal regulations.

HIPAA Authorization for Research Use of Protected Health Information

By signing this consent form, you are also authorizing the study team to access, use, and disclose your Protected Health Information (PHI) as defined under HIPAA for the purposes of conducting this clinical trial. The information that may be used or disclosed includes: medical history, laboratory results, imaging reports, physical examination findings, and any other health data relevant to the study protocol. Authorized recipients of your PHI include: the study sponsor (and its agents), the IRB, regulatory agencies (FDA, EMA), and study monitoring bodies. You have the right to revoke this authorization at any time in writing; however, revocation will not affect uses already made during your participation. Your refusal to authorize use of your PHI will result in your ineligibility for this study.

Compensation and Study Costs Summary

Compensation: [Specify: e.g. no compensation / $X per completed visit / travel reimbursement up to $X]. All study-required procedures, laboratory tests, and investigational drugs provided as part of this trial will be at no cost to you. Standard-of-care procedures that would be performed regardless of study participation may be billed to your insurance. Any injury directly caused by study procedures will be treated at no cost to you. Compensation for study-related injuries beyond treatment costs is not available unless otherwise specified by the sponsor. If you believe you have been injured as a result of this research, contact [Study Injury Contact].

Right to Withdraw Without Penalty

Your participation in this clinical trial is entirely voluntary. You may withdraw at any time for any reason without penalty, loss of benefits to which you are otherwise entitled, or adverse effect on your relationship with the clinical team. Withdrawal from the study will not affect your access to standard medical care. If you withdraw, any data or samples collected before withdrawal may be retained and used in the study analysis unless you specifically request their destruction in writing.

Language Access and Interpreter Services

If English is not your primary language or if you have difficulty reading, a qualified interpreter is available to translate this document or read it aloud to you at no cost. The IRB-required short form process for non-English speakers will be followed if applicable. Please notify the study coordinator before signing this document.

Copy of Consent Acknowledgment

Federal regulations (21 CFR 50.27 and 45 CFR 46.117) require that you receive a signed copy of this informed consent document. I acknowledge that I have received a copy of this signed consent form for my own records.

Participant Authorization

I confirm that I have read or had read to me this consent form. All my questions have been answered to my satisfaction. I voluntarily agree to participate in this study. I understand I may withdraw at any time without penalty. I authorize the use and disclosure of my health information for the purposes of this study as described above.

Signatures and Verification